Archive by Author

Interview with Dr. Gennady Bratslavsky (Avicella Capital) on RESI Experience from an Investor’s Point of View

1 Feb
Dr.-Gennady-Bratslavsky
Dr. Gennady Bratslavsky		 Interview with Dr. Gennady Bratslavsky, Co-Founder & Partner at Avicella Capital

By Momo Yamamoto, Investor Research Analyst, LSN

 Momo Yamamoto

Hear from Investor RESI attendee, Dr. Gennady Bratslavsky, Co-Founder & Partner at Avicella Capital, and learn more about Avicella Capital’s investment interests and gain insight into the RESI experience from an investor point of view. Dr. Bratslavsky touches on different aspects of the RESI conference and how this works well for him in sourcing early-stage investment deals.

Click Here to Listen the Interview

LSN Offers Free Webinars in Preparation for a Successful RESI South

1 Feb

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wpPartnering events are a pivotal tool to engage with potential investors and strategic partners in the early-stage arena – they are a great way to gain exposure and feedback, as well as building critical relationships. Life Science Nation is offering a series of free webinars to help life science and healthcare entrepreneurs put their best foot forward at partnering events, in preparation for the upcoming RESI South partnering conference, on Monday, March 25 in Atlanta. These free webinars offer tactical advice to early-stage companies on how to maximize outcomes when attending conferences like RESI and moving connections beyond the event. Attend these complimentary webinars Life Science Nation offers.

Register or listening to previous recordings at the links below:

RESI South Preparation Webinar Series
Tuesday, January 23 12PM ET
Startup CEOs Global Partnering Strategy Webinar Recording
Tuesday, February 6, 12PM ET
Preparing for the Innovator’s Pitch Challenge (IPC) at RESI South Sign Up
Tuesday, February 20, 12PM ET
Presenting to Investors: Compelling Story vs Pitch Deck Sign Up
Tuesday, March 5, 12PM ET
The LSN Event Partnering Process Sign Up
Tuesday, March 19, 12PM ET
Investor Fireside Chat Sign Up

RESI-South-2024-11oo

Hot Investor Mandate: Family-Run Investment Vehicle Invests in Early-Stage Therapeutics Companies With a Strong Focus on Rare Disease Assets

1 Feb

A family-run investment and commercialization vehicle invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs. 
 
The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also attractive to the firm. 
 
The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Life Science Tools Manufacturer Partners and Invests in Tools, Lab Equipment, AI-Leveraging Companies, in North America & Europe

1 Feb

A life science research tools manufacturer with worldwide offices is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the company’s selected application fields. 
 
The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm’s early stage partnering arm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology. 
 
The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm’s early stage partnering arm is a corporate venture fund with a charter towards select, new business line-directed equity investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Invests in Therapeutics, Devices, and Digital Health/Wellness Companies Targeting CNS, Mental & Behavioral Diseases, and More

1 Feb

A venture capital firm based in the US is actively investing from their second fund. The firm is actively investing in the intersection of science, technology, and neurology, and has invested in over 30 companies to date. The firm invests primarily in Seed to Series A rounds. While the firm has mostly invested in USA-based companies, the firm is open to opportunities beyond. 
 
Within life sciences, the firm is interested in drug development and drug development-enabling tools and technologies, medical devices with a software component, and wearables. Relating to therapeutics, the firm is particularly interested in psychedelics and plant-based therapies. The firm is most interested in technologies that target mental & behavioral health and CNS/neurodegenerative disease. The firm is open to early-stage, pre-clinical companies. 
 
The firm has no specific company or management team requirements, and is open to acting as either lead or co-investor, seeking board representation when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Biotech-Focused Fund Invests Actively in Therapeutics and Digital Health Technologies Interested in Expanding to Japanese Market

1 Feb

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market. 
 
The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond. 
 
The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

How do Accelerators, Incubators, Universities, and More Collaborate with Life Science Nation and RESI conferences? 

29 Jan

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation’s RESI conferences aren’t just limited to early-stage life science startups and investors. There’s also another yet equally important group in this space: tech hubs.  

Tech hubs comprise of incubators, accelerators, non-profits, universities, and government organizations. A special thank you to our tech hubs at RESI JPM 2024 Arizona Bioindustry Association (AZBio), BIOCAT, Brisbane Economic Development Agency (BEDA), California Life Sciences (CLS), Connect, Duke Clinical Research Institute, Endless Frontiers Labs, Enterprise Singapore, Frederick National Laboratory, Life Sciences BC, MaRS Discovery District, Monash University, National Cancer Institute (NCI), Nest Catalyst, NLC, Ontario Brain Institute, Ontario Bioscience Innovation Organization (OBIO), The Ganesha Lab, and Trade and Investment Queensland. These tech hubs attended RESI to learn from and partner with other startups and investors. 

Here are different ways that tech hubs interact with Life Science Nation (LSN) and the RESI conferences: 

Tech hubs & RESI collaboration: 

  1. Ability to meet with investors, startups, and service providers
  2. Ability to host an exhibition table and/or workshop with sponsorship

  3. Ability to sponsor an Innovator’s Pitch Challenge (IPC) session featuring your startups in the same sector

  4. Discounted rates! Promote a unique discount code for the “tech hub rate”. After 1 startup registers using the unique discount code, then 1 tech hub staff will get free registration to RESI 

Tech hubs & LSN (non-RESI collaboration): 

  1. Sponsor an in-person or virtual education course for selected startups. In 2023, we hosted education courses with BioMedSA, CLS, Georgia Bio, GA Tech VentureLab, HKSTP, Government of Ontario, OBIO, and BEDA.

  2. Sponsor the LSN Investor Database subscription for your startups 

Interest in attending an upcoming RESI? Our next RESI is in Atlanta, March 25-27. The first day on March 25th will be held in-person in Atlanta, Georgia at The Whitely Hotel (Buckhead) with 1-1 partnering meetings, Innovator’s Pitch Challenge (IPC) sessions, investor-led panels, sponsored workshops, exhibition, and a cocktail reception. The remaining two days, March 26-27th, will be virtual 1-1 partnering meetings only. The partnering platform LSN uses for RESI is called Meeting Mojo which will be launched 3 weeks beforehand for attendees to utilize to book meetings.

Contact Erika Wu e.wu@lifesciencenation.com for the discounted “tech hub rate” or any other questions you may have about joining LSN as a tech hub. 

RESI-South-2024-11oo

← Older Entries
Newer Entries →